OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.47

+8.5%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$61.12M
EPS-4.4000
P/E Ratio-1.02
Earnings Date08/11/2026

okur

Other Non-Cash Items

Last Annual Value

6.00K

3-Year CAGR

%

5-Year CAGR

-56%

10-Year CAGR

-34%

OT

OnKure Therapeutics, Inc. Competitors Analysis of Other Non-Cash Items

OKUR · NASDAQ
CompanyOther Non-Cash Items
CAGR 3Y
CAGR 5Y
CAGR 10Y
6.00K
N/A-73.4%N/A 
1.08B
733.1%437.7%139.3%
1.80M
N/A81.7%6.3%
-60.50M
N/AN/AN/A
1.08M
313.6%-2.5%3.7%
-3.56M
N/AN/AN/A
0.00
N/AN/AN/A
-496.00K
N/AN/AN/A
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.47, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.47